Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Vivek Subbiah; Philippe A. Cassier; Salvatore Siena; Elena Garralda; Luis Paz-Ares; Pilar Garrido; Ernest Nadal; Jacqueline Vuky; Gilberto Lopes; Gregory P. Kalemkerian

doi:10.1038/s41591-022-01931-y

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Identifier:nobleid.org/w1/20260526/D79529DF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D79529DF.svg?ark=w1%2F20260526%2FD79529DF)](https://nobleid.org/work/w1/20260526/D79529DF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Gregory P. Kalemkerian

Claim authorship of this work

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Identifier:nobleid.org/w1/20260526/D79529DF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D79529DF.svg?ark=w1%2F20260526%2FD79529DF)](https://nobleid.org/work/w1/20260526/D79529DF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Gregory P. Kalemkerian

Claim authorship of this work